News

Hospitals already using the technologies are required to report to the ministry for verification of qualifications within six months of that date. The ministry said its aim is

For the year ended December 31, 2008, revenues were C$52.6 million, compared to nil revenues for the year ended December 31, 2007. Net loss was C$0.5 million, or

For the full year 2008, the company reported a net loss of $59.82 million, or $2.90 per share, compared to a net loss of $31.86 million, or $2.17

Toctino is a once-daily oral therapy for the treatment of adults that is given for 12 to 24 weeks, depending on patient response. In the six-month post-treatment observation

China Sky One Medical, a fully integrated pharmaceutical company, has obtained approval from the State Food and Drug Administration in China for the production of Policresulen vaginal suppositories.

Mr VanOort also joined the company’s board of directors. As part of this move, NeoGenomics has modified its by-laws to increase the size of its board of directors

The funding has been awarded to the ‘cancer anti-invasive program’ (CAP) private-public consortium as part of OSEO’s strategic industrial innovation scheme. The consortium led by BioAlliance Pharma comprises

As part of the transaction, Michael Ross, managing partner at SV Life Sciences, and Joseph Amprey, senior managing director of MedImmune Ventures, joined the NKT Therapeutics board. NKT

Durezol, developed and marketed by Sirion Therapeutics, was previously approved by the FDA for the treatment of post-operative inflammation and pain associated with ocular surgery. The supplemental application